The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified vaccine PLLAV-YF17D/RabG for the prevention of rabies. The public consultation runs from 20 December 2023 to 19 January 2024.
For each clinical trial application for the use of a genetically modified organism, the government organises a thirty-day public consultation, in accordance with the Royal Decree of 21 February 2005. As a citizen, you can give your opinion on this clinical trial application with a genetically modified vaccine.
Rabies is caused by the rabies virus: a very dangerous virus that can infect humans as well as animals, such as dogs, bats and foxes.
In this clinical trial, the vaccine PLLAV-YF17D/RabG will be administered to healthy adults aged 18 to 40 years. The vaccine was made by adding the genetic code for the surface protein of the rabies virus (RabG) to that of the yellow fever vaccine strain 17D (YF17D). The vaccine YF17D is used since 1938 to protect people against yellow fever.
The aim of this trial is to assess the safety, reactogenicity and immunogenicity of the PLLAV-YF17D/RabG vaccine.
The clinical trial will take place at the Center for Evaluation of Vaccination (CEV)/Vaccinopolis in Antwerp (Edegem) and at the Center of Vaccinology (CEVAC) in Ghent.
How to give your opinion?
The public consultation runs until 19 January 2024 inclusive. You can access the various data in the application file, as well as an online form to send your comments or ask your questions.